立体定向放射外科治疗复发或残留无功能垂体腺瘤的长期影像学与内分泌学结局
这项回顾性多中心研究纳入接受单次立体定向放射外科治疗的复发或残留无功能垂体腺瘤患者,肿瘤控制组360例、垂体功能低下组351例。5年、8年、10年、15年肿瘤控制率分别为93%、87%、86%、69%,垂体功能保留率分别为83%、81%、78%、71%。边缘剂量>15 Gy和末次手术至放射外科间隔>1年与肿瘤控制相关,垂体柄最大剂量≤10 Gy与垂体功能保留相关。
要点
- 5年、8年、10年、15年肿瘤控制率分别为93%、87%、86%、69%。
- 5年、8年、10年、15年垂体功能保留率分别为83%、81%、78%、71%。
- 边缘剂量>15 Gy与末次手术至放射外科间隔>1年与肿瘤控制相关。
核心结论
- 立体定向放射外科为绝大多数无功能垂体腺瘤提供良好且持久的肿瘤控制。
- 放射外科后垂体功能低下发生于少数患者,但风险随时间增加,需长期随访。
研究设计与样本
- 回顾性多中心研究,纳入接受单次立体定向放射外科治疗的复发或残留无功能垂体腺瘤患者。
- 肿瘤控制组360例,中位年龄52.7岁(IQR 42.9-61),男性193例(53.6%)。
- 垂体功能低下组351例,中位年龄52.5岁(IQR 43-61),男性186例(53.0%)。
- 肿瘤控制评估组中位随访7.95年(IQR 5.7-10.5),内分泌评估组中位随访8年(IQR 5.9-10.7)。
- 采用Cox回归和Kaplan-Meier法分析肿瘤控制和放射外科后新发或加重的垂体功能低下。
主要发现
- 肿瘤控制率5年93%(95% CI 90%-95%)、8年87%(95% CI 83%-91%)、10年86%(95% CI 82%-90%)、15年69%(95% CI 59%-81%)。
- 垂体功能保留率5年83%(95% CI 80%-87%)、8年81%(95% CI 77%-85%)、10年78%(95% CI 74%-83%)、15年71%(95% CI 63%-79%)。
- 多因素分析中,边缘剂量>15 Gy(HR 0.8,95% CI 0.7-0.9;p<0.001)和末次手术至放射外科间隔>1年(HR 0.9,95% CI 0.7-0.9;p=0.04)与肿瘤控制显著相关。
- 垂体柄最大剂量≤10 Gy(HR 1.1,95% CI 1.09-1.2;p<0.001)与垂体功能保留相关。
- 放射外科后新发视觉缺损在肿瘤控制组7例(1.94%)、内分泌组8例(2.3%);其他新发颅神经缺损在肿瘤控制组160例有数据者中4例、内分泌组140例有数据者中3例。
关键数值与推荐
- 肿瘤控制率5年93%(95% CI 90%-95%)、8年87%(95% CI 83%-91%)、10年86%(95% CI 82%-90%)、15年69%(95% CI 59%-81%)。
- 垂体功能保留率5年83%(95% CI 80%-87%)、8年81%(95% CI 77%-85%)、10年78%(95% CI 74%-83%)、15年71%(95% CI 63%-79%)。
- 边缘剂量>15 Gy(HR 0.8,95% CI 0.7-0.9;p<0.001)与肿瘤控制显著相关。
- 末次手术至放射外科间隔>1年(HR 0.9,95% CI 0.7-0.9;p=0.04)与肿瘤控制显著相关。
- 垂体柄最大剂量≤10 Gy(HR 1.1,95% CI 1.09-1.2;p<0.001)与垂体功能保留相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Stereotactic radiosurgery (SRS) is used for the treatment of residual/recurrent nonfunctional pituitary adenoma (NFPA). The aim of this study was to evaluate the factors related to long-term tumor control and delayed endocrinopathies following SRS. METHODS: This retrospective, multicenter study included patients with recurrent/residual NFPA treated with single-fraction SRS; they were then divided into two arms. The first arm included patients with at least 5 years of radiographic follow-up and all patients with local tumor progression. The second arm included patients with at least 5 years of endocrinological follow-up and all patients who developed endocrinopathy. Study endpoints were tumor control and new or worsening hypopituitarism after SRS and were analyzed using Cox regression and Kaplan-Meier methodology. RESULTS: There were 360 patients in the tumor control arm (median age 52.7 [IQR 42.9-61] years, 193 [53.6%] males) and 351 patients in the hypopituitarism arm (median age 52.5 [IQR 43-61] years, 186 [53.0%] males). The median follow-up in the tumor control evaluation group was 7.95 (IQR 5.7-10.5) years. Tumor control rates at 5, 8, 10, and 15 years were 93% (95% CI 90%-95%), 87% (95% CI 83%-91%), 86% (95% CI 82%-90%), and 69% (95% CI 59%-81%), respectively. The median follow-up in the endocrinopathy evaluation group was 8 (IQR 5.9-10.7) years. Pituitary function preservation rates at 5, 8, 10, and 15 years were 83% (95% CI 80%-87%), 81% (95% CI 77%-85%), 78% (95% CI 74%-83%), and 71% (95% CI 63%-79%), respectively. A margin dose > 15 Gy (HR 0.8, 95% CI 0.7-0.9; p < 0.001) and a delay from last resection to SRS > 1 year (HR 0.9, 95% CI 0.7-0.9; p = 0.04) were significant factors related to tumor control in multivariable analysis. A maximum dose to the pituitary stalk ≤ 10 Gy (HR 1.1, 95% CI 1.09-1.2; p < 0.001) was associated with pituitary function preservation. New visual deficits after SRS occurred in 7 (1.94%) patients in the tumor control group and 8 (2.3%) patients in the endocrinopathy group. Other new cranial nerve deficits post-SRS occurred in 4 of 160 patients with data in the tumor control group and 3 of 140 patients with data in the endocrinopathy group. CONCLUSIONS: SRS affords favorable and durable tumor control for the vast majority of NFPAs. Post-SRS hypopituitarism occurs in a minority of patients, but this risk increases with time and warrants long-term follow-up.
引用
- Shaaban A, Dumot C, Mantziaris G, et al. Long-term radiographic and endocrinological outcomes of stereotactic radiosurgery for recurrent or residual nonfunctioning pituitary adenomas. J Neurosurg. 2024. PMID: 38518285. doi:10.3171/2024.1.JNS232285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。